RTS Acquires Ownership Stake In Hatch Science
RTS is expected to pay a minimum of $500,000. Hatch will join its Life Science division, which has successfully served the North American big pharma, biotech and academic
The US Food and Drug Administration (FDA) has granted priority review to Roche’s supplemental biologics licence application (sBLA) for Gazyva/Gazyvaro (obinutuzumab) to treat adults with primary membranous nephropathy (pMN).